Printer Friendly

Idaho's rejuvenation of the nuclear industry.

Idaho is uniquely able to rejuvenate the nuclear industry because it alone has the necessary advantages for such an achievement. These advantages will be described in the presentation.

Accomplishing these bold objectives will require strong leadership from the Governor, our congressional delegation, in addition to Idaho's scientific, industrial, educational, and commerce leaders. Only a united and sustained effort can drive Idaho's new leadership in nuclear programs.

Idaho can acquire the necessary concessions partly by leveraging the Federal government's unilateral cancelation of the Yucca Mountain repository. Concessions include:

1) All nuclear funding goes to the Lead Nuclear Laboratory and its affiliated universities.

2) A commercial nuclear facility must be built in Idaho by 2030. Several different options are possible.

3) Residual wastes stranded in Idaho receive top priority remediation and long-term storage at INL because of cancelation of Yucca Mt. repository is Federal repudiation of the Batt 2035 agreement.

4) Long-term, above ground, storage facility for commercial spent fuel should be built at INL, pending satisfactory completion of a full-scale spent fuel repository.

The benefits to a scientific, educational, and economic stimulation from Idaho's nuclear leadership are huge.

Blacker, Paul; INL (Retired)

COPYRIGHT 2014 Idaho Academy of Science
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:56TH ANNUAL SYMPOSIUM OF THE IDAHO ACADEMY OF SCIENCE: THEME: ENERGY, MATERIALS, AND NANOTECHNOLOGY
Author:Blacker, Paul
Publication:Journal of the Idaho Academy of Science
Geographic Code:1U8ID
Date:Dec 1, 2014
Words:191
Previous Article:Bio-jet fuel: environmental implications of woody biomass harvest.
Next Article:The effect of proline cistrans isomerization on p53MDM2 binding.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters